Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Pharmaceuticals ETF (IHE) belong to the same industry segment: US Health Care. Both ETFs have the same top 3 sector exposures: and Health Care. FHLC is less expensive with a Total Expense Ratio (TER) of 0.08%, versus 0.38% for IHE. FHLC is down -0.8% year-to-date (YTD) with +$111M in YTD flows. IHE performs better with 4.57% YTD performance, and +$133M in YTD flows. Run a side-by-side ETF comparison of FHLC and IHE below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | FHLC IHE | -1.23%-1.43% | +2.15%+7.02% | -0.80%+4.57% | +8.16%+27.21% | +29.48%+64.45% | +37.11%+63.29% |
| Flows | FHLC IHE | +$34M+$14M | +$130M+$159M | +$111M+$133M | -$10M+$252M | -$619M+$364M | -$233M+$397M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | FHLC IHE | +13.36%+15.90% | +17.33%+20.44% | +13.69%+15.94% | +14.80%+15.80% |
| Max drawdown | FHLC IHE | -5.00%-4.49% | -11.86%-14.18% | -16.88%-16.04% | -17.78%-16.12% |
| Max drawdown duration | FHLC IHE | 61d9d | 190d150d | 435d210d | 762d669d |
FHLC | IHE | |
Last sale 3/11/2026 at 1:30 PM | $72.99 | $88.40 |
| Previous close 03/10/2026 | $73.17 | $88.62 |
| Consolidated volume 03/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
FHLC | IHE | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
FHLC | IHE | |
|---|---|---|
| Last price | $72.99 | $88.40 |
| 1D performance | -0.25% | -0.25% |
| AuM | $2.93 B | $1.02 B |
| E/R | 0.08% | 0.38% |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
